MIM
GALT icon

Monashee Investment Management’s Galectin Therapeutics GALT Stock Holding History

Monashee Investment Management’s Portfolio GALT Stock Details GALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-65,056
Closed -$223K – 133
2018
Q4 		$223K Buy
+65,056
New +$311K 0.15% 70
2018
Q3 		– Hold
0
– – – 129

Other funds holding GALT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DADC
D.A. Davidson & Co Great Falls, Montana $18.1B AUM 24.63% 1-Year Est. Return
AG
Advisor Group Phoenix, Arizona $14.5B AUM 24.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $44.6B AUM 28.94% 1-Year Est. Return

Monashee Investment Management's GALT Position: Q1 2019 in Review

Monashee Investment Management sold out of Galectin Therapeutics (GALT) in Q1 2019, closing a stake of 65,056 shares — an estimated $223K sold.

Monashee Investment Management first reported a position in GALT in Q4 2018 and held it in 1 quarter. The position peaked at $223K in Q4 2018. 65 funds tracked by Wall St. Rank hold GALT as of Q1 2019.

  • Monashee Investment Management reported no remaining Galectin Therapeutics position as of Q1 2019 after selling out during the quarter.
  • Monashee Investment Management sold 65,056 Galectin Therapeutics shares in Q1 2019, an estimated $223K.
  • Monashee Investment Management first reported a position in Galectin Therapeutics in Q4 2018 and held it in 1 quarter.
  • Monashee Investment Management's Galectin Therapeutics position peaked at $223K in Q4 2018.
  • 65 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q1 2019.

Based on Monashee Investment Management's 13F filing for Q1 2019, filed 13 May 2019.